Financials AstraZeneca PLC NYSE

Stocks

AZN

US0463531089

Pharmaceuticals

Real-time Estimate Cboe BZX 14:40:48 2026-09-24 EDT			5-day change	1st Jan Change
165.59 ^USD	+1.38%		+0.27%	+80.30%

12:55am	Nordic stocks in North America, Astra Zeneca fell 1.2%	FW
09-23	Polaris Rx And AstraZeneca Name Polaris Rx Exclusive U.S. Distributor Of AstraZeneca's FluMist® Home Service For Second Consecutive Year	CI

Projected Income Statement: AstraZeneca PLC

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	37,417	44,351	45,811	54,073	58,739	63,166	67,011	71,149
Change	-	18.53%	3.29%	18.03%	8.63%	7.54%	6.09%	6.17%
EBITDA ¹	7,586	9,237	13,580	16,691	19,476	22,193	24,358	26,836
Change	-	21.76%	47.02%	22.91%	16.69%	13.95%	9.76%	10.17%
EBIT ¹	9,928	13,350	14,534	16,928	18,478	21,092	23,268	25,554
Change	-	34.47%	8.87%	16.47%	9.16%	14.15%	10.32%	9.82%
Interest Paid ¹	-862	-1,251	-1,282	-1,284	-1,334	-1,418	-1,114	-925.2
Earnings before Tax (EBT) ¹	-265	2,501	6,899	8,691	12,402	14,981	17,769	20,219
Change	-	1,043.77%	175.85%	25.97%	42.7%	20.79%	18.62%	13.78%
Net income ¹	112	3,288	5,961	7,035	10,225	12,044	13,773	15,801
Change	-	2,835.71%	81.3%	18.02%	45.34%	17.79%	14.36%	14.72%
Announcement Date	2/10/22	2/9/23	2/8/24	2/6/25	2/10/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	9,866	12,011	11,390	10,771	10,982	11,207	10,879	11,416	11,492	12,024	12,679	12,938	13,565	14,891	13,588	14,457	15,191	15,503	15,288	15,384	16,075	16,703	16,075	16,300	16,975	17,495
Change	-	21.74%	-5.17%	-5.43%	1.96%	2.05%	-2.93%	4.94%	0.67%	4.63%	5.45%	2.04%	4.85%	9.78%	-8.75%	6.4%	5.08%	2.05%	-1.39%	0.63%	4.49%	3.91%	-3.76%	1.4%	4.14%	3.06%
EBITDA ¹	1,114	1,900	2,187	1,896	2,579	2,574	-	3,732	-	-	-	4,025	3,923	4,373	4,958	4,897	5,132	4,489	5,612	5,092	7,444	8,153	-	-	-	-
Change	-	70.56%	15.11%	-13.31%	36.02%	-0.19%	-	-	-	-	-	-	-2.53%	11.47%	13.38%	-1.23%	4.8%	-12.53%	25.02%	-9.27%	46.2%	9.52%	-	-	-	-
EBIT ¹	2,281	3,318	3,961	3,365	3,413	2,610	3,946	4,291	3,545	2,752	4,310	4,101	4,318	4,199	4,803	4,584	4,993	4,098	5,352	5,158	5,436	5,201	-	-	-	-
Change	-	45.46%	19.38%	-15.05%	1.43%	-23.53%	51.19%	8.74%	-17.39%	-22.37%	56.61%	-4.85%	5.29%	-2.76%	14.38%	-4.56%	8.92%	-17.93%	30.6%	-3.62%	5.39%	-4.32%	-	-	-	-
Charge d'intérêts	-219	-234	-319	-293	-324	-315	-287	-262	-291	-337	-302	-285	-274	-365	-215	-371	-349	-349	-	-355	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-2,001	-636	553	247	922	778	2,262	2,088	1,652	897	2,800	2,397	1,828	1,666	-	3,127	3,244	-	3,914	2,799	4,958	4,319	-	-	-	-
Change	-	68.22%	186.95%	-55.33%	273.28%	-15.62%	190.75%	-7.69%	-20.88%	-45.7%	212.15%	-14.39%	-23.74%	-8.86%	-	-	3.74%	-	-	-28.49%	77.13%	-12.89%	-	-	-	-
Net income ¹	-1,652	-347	386	360	1,640	901	1,803	1,818	1,378	959	2,179	1,927	1,429	1,500	2,916	2,450	2,533	2,326	3,080	2,507	3,606	4,038	-	-	-	-
Change	-	79%	211.24%	-6.74%	355.56%	-45.06%	100.11%	0.83%	-24.2%	-30.41%	127.22%	-11.56%	-25.84%	4.97%	94.4%	-15.98%	3.39%	-8.17%	32.42%	-18.6%	43.85%	11.98%	-	-	-	-
Announcement Date	11/12/21	2/10/22	4/29/22	7/29/22	11/10/22	2/9/23	4/27/23	7/28/23	11/9/23	2/8/24	4/25/24	7/25/24	11/12/24	2/6/25	4/29/25	7/29/25	11/6/25	2/10/26	4/29/26	7/27/26	-	-	-	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2024 S1
Net sales ¹	25,617
Change	-
EBITDA	-
Change	-
EBIT ¹	8,411
Change	-
Charge d'intérêts	-
Earnings before Tax (EBT)	-
Change	-
Net income	-
Change	-
Announcement Date	7/25/24

¹USD in Million

Estimates

Forecast Balance Sheet: AstraZeneca PLC

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt ¹	24,383	22,923	22,510	24,570	23,374	19,694	11,931	3,188
Change	-	-5.99%	-1.8%	9.15%	-4.87%	-15.74%	-39.42%	-73.28%
Announcement Date	2/10/22	2/9/23	2/8/24	2/6/25	2/10/26	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: AstraZeneca PLC

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
CAPEX ¹	1,091	1,091	1,361	1,924	2,810	3,232	3,305	3,466
Change	-	0%	24.75%	41.37%	46.05%	15.01%	2.25%	4.88%
Free Cash Flow (FCF) ¹	4,872	8,717	8,984	9,937	11,765	9,594	13,010	14,622
Change	-	78.92%	3.06%	10.61%	18.4%	-18.45%	35.61%	12.38%
Announcement Date	2/10/22	2/9/23	2/8/24	2/6/25	2/10/26	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: AstraZeneca PLC

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	20.27%	20.83%	29.64%	30.87%	33.16%	35.13%	36.35%	37.72%
EBIT Margin (%)	26.53%	30.1%	31.73%	31.31%	31.46%	33.39%	34.72%	35.92%
EBT Margin (%)	-0.71%	5.64%	15.06%	16.07%	21.11%	23.72%	26.52%	28.42%
Net margin (%)	0.3%	7.41%	13.01%	13.01%	17.41%	19.07%	20.55%	22.21%
FCF margin (%)	13.02%	19.65%	19.61%	18.38%	20.03%	15.19%	19.42%	20.55%
FCF / Net Income (%)	4,350%	265.12%	150.71%	141.25%	115.06%	79.66%	94.46%	92.54%
Profitability
ROA	8.77%	3.26%	11.48%	12.51%	13.12%	13.25%	14.01%	14.54%
ROE	27.51%	27.23%	29.77%	32.11%	31.99%	30.31%	29.92%	28.8%
Financial Health
Leverage (Debt/EBITDA)	3.21x	2.48x	1.66x	1.47x	1.2x	0.89x	0.49x	0.12x
Debt / Free cash flow	5x	2.63x	2.51x	2.47x	1.99x	2.05x	0.92x	0.22x
Capital Intensity
CAPEX / Current Assets (%)	2.92%	2.46%	2.97%	3.56%	4.78%	5.12%	4.93%	4.87%
CAPEX / EBITDA (%)	14.38%	11.81%	10.02%	11.53%	14.43%	14.56%	13.57%	12.92%
CAPEX / FCF (%)	22.39%	12.52%	15.15%	19.36%	23.88%	33.69%	25.4%	23.7%
Items per share
Cash flow per share ¹	4.179	6.287	6.623	7.589	9.331	11.43	12.65	14.43
Change	-	50.46%	5.34%	14.58%	22.96%	22.47%	10.72%	14.01%
Dividend per Share ¹	2.87	2.9	2.9	3.1	3.2	3.34	3.544	3.655
Change	-	1.05%	0%	6.9%	3.23%	4.37%	6.1%	3.13%
Book Value Per Share ¹	27.69	23.93	25.06	26.09	31.16	34.81	39.87	46.11
Change	-	-13.6%	4.74%	4.13%	19.4%	11.73%	14.53%	15.66%
EPS ¹	0.08	2.11	3.81	4.5	6.54	7.844	8.987	10.37
Change	-	2,537.5%	80.57%	18.11%	45.33%	19.93%	14.58%	15.36%
Nbr of stocks (in thousands)	1,549,159	1,549,528	1,549,926	1,550,317	1,550,726	1,551,024	1,551,024	1,551,024
Announcement Date	2/10/22	2/9/23	2/8/24	2/6/25	2/10/26	-	-	-